BN Business News
Add your company to Business Communicator →

International trade · 12/05/2006Updated: 10/17/2026 · 1 min read

Notice of Investigation into Alleged Patent Infringement of Recombinant Human Erythropoietin Products

Summary

The U.S. International Trade Commission has received a complaint from Amgen Inc. regarding alleged patent infringement by companies importing products containing recombinant human erythropoietin into the United States. Amgen is seeking a permanent exclusion order and cease and desist orders.

Original source language: Federal Register — International Trade CommissionOpen original release →

Explore insights

Business insights →